Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Diabetes Care

• Publication date

  2007-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/dc06-2562PMID 17392534
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome

  2007cited by this paper
• Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.

  2006cited by this paper
• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

  2006cited by this paper
• Antihypertensive Medications and the Risk of Incident Type 2 Diabetes

  2006cited by this paper
• Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.

  2006influential reference
• Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

  2003cited by this paper

• Diuretics: a review of the pharmacology and effects on glucose homeostasis

  2025cites this paper
• Effect of Verapamil on Blood Glucose in Type 1 and Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

  2025cites this paper
• Hypertension in metabolic syndrome

  2025cites this paper
• Arterial hypertension in metabolic syndrome, 2024

  2024cites this paper
• Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus

  2024cites this paper
• Effects of thiazides and new findings on kidney stones and dysglycemic side effects

  2024cites this paper
• Thiazides Attenuate Insulin Secretion Through Inhibition of Mitochondrial Carbonic Anhydrase 5b in β-Islet Cells in Mice

  2023cites this paper
• Synthesize heterogeneous biological knowledge via representation learning for Alzheimer’s disease drug repurposing

  2022cites this paper
• Thiazides induce glucose intolerance through inhibition of mitochondrial carbonic anhydrase 5b in β-cells

  2022cites this paper
• An overview of the effects of combination therapy with a renin-angiotensin system blocker plus a calcium channel blocker on glucose homeostasis in non-diabetic hypertensive patients

  2022cites this paper
• Position statement on use of pharmacological combinations in a single pill for treatment of hypertension by Argentine Federation of Cardiology (FAC) and Argentine Society of Hypertension (SAHA)

  2021cites this paper
• Deep Learning for Alzheimer's Disease Drug Repurposing using Knowledge Graph and Multi-level Evidence

  2021cites this paper
• How to Manage Hypertension in People with Diabetes.

  2020cites this paper
• Treatment of arterial hypertension in metabolic syndrome

  2020cites this paper
• A Prospective Noninterventional, Observational Study to Describe the Effectiveness and Safety of Trandolapril and Verapamil Single-Pill Combination in the Management of Patients with Hypertension and Type 2 Diabetes Mellitus: A Harvest TR Study

  2020cites this paper
• Thiazide Diuretic–Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials

  2020cites this paper
• Hypertension News-Screen: Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase-4 trial

  2019cites this paper
• Hypertension and Diabetes

  2019cites this paper
• Hypertonie und Diabetes: Hypertonie bei metabolischem Syndrom: Epidemiologie, Bedeutung, Pathogenese und Therapie

  2019influential citation
• The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.

  2019cites this paper
• Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline.

  2019cites this paper
• Возможности применения комбинированной терапии верапамилом СР и трандолаприлом у больных артериальной гипертонией в группах высокого риска Combination of verapamil and trandolapril: therapeutic potential for high*risk patients with arterial hypertension

  2018cites this paper
• Impact of long-term potassium supplementation on thiazide diuretic-induced abnormalities of glucose and uric acid metabolisms

  2018cites this paper
• Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study

  2018cites this paper
• Combination therapy in the treatment of hypertension

  2018cites this paper
• Evaluation and Treatment of Hypertension

  2018cites this paper
• The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis

  2018cites this paper
• Association of a Multi-Gene Panel with Blood Pressure Medication Success in Patients with Hypertension: A Pilot Study

  2018cites this paper
• A review of chemical therapies for treating diabetic hypertension

  2017cites this paper
• [Pathophysiology of hypertension secondary to obesity].

  2017cites this paper
• Focus on arterial stiffness

  2017cites this paper
• Účinná a bezpečná terapie arteriální hypertenze u obézního pacienta s metabolickým syndromem

  2016cites this paper
• Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension.

  2016cites this paper
• Preventing new-onset diabetes in thiazide-treated patients.

  2016cites this paper
• The Results of ACES (Antihypertensive Combinations’ Long Term Efficacy Comparing Study): Analysis of Metabolic Effects of Antihypertensive Combination Therapies

  2016cites this paper
• Cardiovascular Risk Assessment, Summary of Guidelines for the Management of Hypertension and a Critical Appraisal of the 2014 Expert Panel of the National Institutes of Health Report

  2016cites this paper
• A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.

  2016cites this paper
• Safe and effective antihypertensive therapy in obesity

  2016cites this paper
• Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial

  2016cites this paper
• Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension

  2015influential citation
• Impact of Chronic Kidney Disease and Diabetes Mellitus on Choice of Renin Angiotensin System-Inhibitors in Patients with Hypertension and Heart Failure

  2015cites this paper
• Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?

  2015cites this paper
• Comparison of Azelnidipine and Trichlormethiazide in Japanese Type 2 Diabetic Patients with Hypertension: The COAT Randomized Controlled Trial

  2015cites this paper
• The Impacts of Obesity on the Cardiovascular and Renal Systems: Cascade of Events and Therapeutic Approaches

  2015cites this paper
• Drug Safety and Effectiveness Network Report: A Systematic Review with Network Meta-Analyses and Economic Evaluation Comparing Therapies for Hypertension in Non-Diabetic Patients

  2014cites this paper
• Efficacy and Safety of a Lercanidipine/Enalapril Fixed-Dose Combination in Hypertensive Patients in Portugal

  2014cites this paper
• A randomised controlled trial for the evaluation of risk for type 2 diabetes in hypertensive patients receiving thiazide diuretics: Diuretics In the Management of Essential hypertension (DIME) study

  2014cites this paper
• Determinants of medium-term blood pressure variability and the related risks of stroke and dementia

  2014cites this paper
• This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted PDF and full text (HTML) versions will be made available soon.

  2014cites this paper
• Domestic practice of antihypertensive treatment of diabetic hypertensive patients

  2014cites this paper
• Influence of angiotensin II receptor blocker combination tablet prescription on drug number and cost

  2014cites this paper
• Anti-hypertensive strategies in patients with MEtabolic parameters, DIabetes mellitus and/or NephropAthy (the M E D I N A study).

  2013cites this paper
• [Advantages of ramipril/amlodipin fixed combination therapy. When should we use it?].

  2013cites this paper
• Which is a Better Treatment for Hypertensive Patients with Diabetes: A Combination of Losartan and Hydrochlorothiazide or a Maximum Dose of Losartan?

  2013cites this paper
• Impact of chronic diuretic treatment on glucose homeostasis

  2013cites this paper
• The metabolic cost of lowering blood pressure with hydrochlorothiazide

  2013cites this paper
• A Review of the Efficacy and Tolerability of Combination Amlodipine/Valsartan in Non-White Patients with Hypertension

  2013cites this paper
• Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.

  2013cites this paper
• Morbus diureticus in the elderly: epidemic overuse of a widely applied group of drugs.

  2013cites this paper
• [Combination therapy in the management of hypertension - current problem in Poland. Expert consensus statement of the Polish Society of Hypertension and Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy].

  2013cites this paper
• Effects of a fixed combination of losartan with hydrochlorothiazide on glucose tolerance in hypertensive patients uncontrolled with angiotensin ii receptor blockers alone.

  2013cites this paper
• Changes in biomarkers and 24 hours blood pressure in hypertensive African Americans with the metabolic syndrome: comparison of amlodipine/olmesartan versus hydrochlorothiazide/losartan.

  2013cites this paper
• Diuretic-based regimens for obese patients?

  2013cites this paper
• Renal Disease in Diabetes Mellitus: Recent Studies and Potential Therapies

  2013cites this paper
• Treatment of Hypertension in the Metabolic Syndrome

  2013cites this paper
• Interaction by known beta cell loci on the association of antihypertensive drug therapies with hyperglycemia in the Framingham Offspring Study

  2013influential citation
• 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

  2013cites this paper
• Antihypertensive Therapy and New-Onset Diabetes

  2012cites this paper
• What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels? Pro and Cons

  2012influential citation
• Fixed-Dose Combinations as Initial Therapy for Hypertension

  2012cites this paper
• Does Response of RAS Blockade on Serum K+ Levels Influence Its Glycemic‐Mitigating Response When Combined With Hydrochlorothiazide?

  2012cites this paper
• A Double-Blind, Placebo-Controlled, Crossover Trial Comparing the Effects of Amiloride and Hydrochlorothiazide on Glucose Tolerance in Patients With Essential Hypertension

  2012cites this paper
• The Role of ARBs Alone or with HCTZ in the Treatment of Hypertension and Prevention of Cardiovascular and Renal Complications

  2012cites this paper
• Spironolactone Prevents Chlorthalidone-Induced Sympathetic Activation and Insulin Resistance in Hypertensive Patients

  2012cites this paper
• Evidence‐Based Hypertension Treatment in Patients With Diabetes

  2012cites this paper
• Amlodipine/Valsartan

  2012cites this paper
• Position Statement Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group Cardiometabolic Risk Working Group: Executive Committee:

  2011cites this paper
• Initial hypertension treatment: one combination fits most?

  2011cites this paper
• Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary).

  2011cites this paper
• Single-Pill Telmisartan and Amlodipine

  2011cites this paper
• [Prevention of progression and regression of target organ damage. Future strategies].

  2011cites this paper
• Impact of trandolapril therapy and its combination with a calcium channel blocker on plasma adiponectin levels in patients with type 2 diabetes and hypertension

  2011cites this paper
• アンジオテンシンII 1型受容体拮抗薬からロサルタン・ヒドロクロロチアジド合剤への変更が血圧, 腎臓, 代謝に与える影響 血圧コントロールが不十分な2型糖尿病患者における検討 (KOLABO study)

  2011cites this paper
• Cardiovascular Risk Assessment and Summary of Guidelines for the Management of Hypertension

  2011cites this paper
• The role of fixed-dose combinations in the treatment of hypertension — expert opinion

  2011cites this paper
• Valsartan Improves b-Cell Function and Insulin Sensitivity in Subjects With Impaired Glucose Metabolism

  2011cites this paper
• Valsartan Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Glucose Metabolism

  2011cites this paper
• Use of Combination Therapy in Special Populations

  2011cites this paper
• A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients

  2011cites this paper
• Potassium and risk of Type 2 diabetes

  2011cites this paper
• The metabolic approach The must of our age

  2011cites this paper
• Position Statement Identification and Management of Cardiometabolic Risk in Canada: A Position Paper by the Cardiometabolic Risk Working Group (Executive Summary)

  2011cites this paper
• Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group.

  2011cites this paper
• Hydrochlorothiazide Versus Calcium Channel Blockers: What is the Best Add-on to a Renin-Angiotensin System Blocker for Treating Hypertension in Patients with Renal Disease?

  2011cites this paper
• Switching Therapy from Variable-Dose Multiple Pill to Fixed-Dose Single-Pill Combinations of Angiotensin II Receptor Blockers and Thiazides for Hypertension

  2011cites this paper
• Single-pill combination — role in antihypertensive therapy

  2011cites this paper
• Hypertension 2010: what was new for the cardiologist?

  2010cites this paper
• Reviewtherapy in hypertension: An update

  2010cites this paper
• Chapter 4 – Hypertensive Kidney Disease

  2010cites this paper
• A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome

  2010cites this paper